文献速递细菌感染、耐药与抗菌药物

乌克兰2016-17年抗生素耐药性调查:基于CLSI、EUCAST和PK/PD折点的数据

Results from the Survey of Antibiotic Resistance (SOAR) 2016-17 in Ukraine: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints.
PubMed 文献 · J Antimicrob Chemother · 2020-01-01

该研究测定了2016-17年乌克兰社区获得性呼吸道感染分离的177株病原体(78株肺炎链球菌和99株流感嗜血杆菌)的抗生素敏感性,并采用CLSI、EUCAST(剂量特异性)和PK/PD折点进行评估。结果显示,总体敏感性较高,但不同折点间差异显著,尤其头孢克洛。数据有助于指导社区获得性呼吸道感染的经验性治疗。

要点

  • 肺炎链球菌对青霉素的敏感性因折点而异:CLSI静脉高剂量或EUCAST高剂量下约98%敏感,而口服或低剂量静脉折点下为73.1%。
  • 流感嗜血杆菌几乎均为β-内酰胺酶阴性(90.9%),对大多数抗生素敏感性高,但EUCAST口服头孢呋辛折点下仅10.1%敏感。
  • 所有肺炎链球菌和流感嗜血杆菌对氟喹诺酮类均敏感,对头孢曲松的敏感性分别为≥91%和100%。

核心结论

  • 乌克兰社区获得性呼吸道病原体对抗生素的敏感性总体较高。
  • 不同折点(CLSI、EUCAST、PK/PD)下敏感性结果差异显著,尤其头孢克洛。
  • 数据对社区获得性呼吸道感染的经验性治疗选择具有参考价值。

研究设计与样本

  • 研究共收集177株临床分离株,包括78株肺炎链球菌和99株流感嗜血杆菌。
  • 采用CLSI肉汤微量稀释法测定MIC,并用CLSI、EUCAST(剂量特异性)和PK/PD折点评估敏感性。

主要发现

  • 肺炎链球菌对青霉素:CLSI静脉高剂量或EUCAST高剂量折点下约98%敏感,CLSI口服或EUCAST低剂量静脉折点下73.1%敏感。
  • 肺炎链球菌对大多数抗生素敏感性为76.9%-100%,但甲氧苄啶/磺胺甲噁唑为41%-69.2%;头孢克洛敏感性分别为EUCAST 0%、PK/PD 28.2%、CLSI 73.1%。
  • 流感嗜血杆菌中90.9%为β-内酰胺酶阴性;CLSI折点下除甲氧苄啶/磺胺甲噁唑(61.6%)外,所有测试抗生素敏感性≥90.9%。
  • 流感嗜血杆菌对氨苄西林(EUCAST 90.9%)和阿莫西林/克拉维酸(95%)敏感性相似,但口服头孢呋辛仅10.1%敏感。
  • 所有肺炎链球菌和流感嗜血杆菌对氟喹诺酮类均敏感;头孢曲松敏感性分别为≥91%和100%。

关键数值与推荐

  • 肺炎链球菌对青霉素敏感性:CLSI静脉高剂量或EUCAST高剂量折点下约98%,CLSI口服或EUCAST低剂量静脉折点下73.1%。
  • 肺炎链球菌对甲氧苄啶/磺胺甲噁唑敏感性41%-69.2%;对头孢克洛敏感性EUCAST 0%、PK/PD 28.2%、CLSI 73.1%。
  • 流感嗜血杆菌β-内酰胺酶阴性率90.9%;CLSI折点下对甲氧苄啶/磺胺甲噁唑敏感性61.6%。
  • 流感嗜血杆菌对口服头孢呋辛(EUCAST)敏感性10.1%;对氨苄西林(EUCAST)90.9%,阿莫西林/克拉维酸(EUCAST)95%。
  • 所有菌株对氟喹诺酮类敏感;头孢曲松对流感嗜血杆菌敏感性100%,对肺炎链球菌≥91%。

临床怎么用

  • 经验性治疗社区获得性呼吸道感染时,应关注当地病原体敏感性及折点选择对结果的影响。
  • 对于肺炎链球菌,高剂量青霉素或阿莫西林/克拉维酸可能覆盖更多菌株,但需结合临床情况。
  • 流感嗜血杆菌对口服头孢呋辛敏感性低,可能不宜作为经验性用药。

局限性

  • 研究仅纳入乌克兰2016-17年的177株分离株,样本量有限,代表性需谨慎。
  • 未报告患者临床特征、感染部位及预后数据。
  • 不同折点间比较为实验室数据,未与临床疗效关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To determine antibiotic susceptibility of Streptococcus pneumoniae and Haemophilus influenzae isolates from community-acquired respiratory tract infections (CA-RTIs) collected in 2016-17 from Ukraine. METHODS: MICs were determined by CLSI broth microdilution and susceptibility was assessed using CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. RESULTS: A total of 177 viable clinical isolates, including 78 S. pneumoniae and 99 H. influenzae, were collected. Overall, ∼98% of S. pneumoniae isolates were susceptible to penicillin by CLSI IV or EUCAST high-dose breakpoints and 73.1% were susceptible by CLSI oral or EUCAST low-dose IV breakpoints. Susceptibility rates of 76.9%-100% were observed for most antibiotics by all breakpoints except trimethoprim/sulfamethoxazole (41%-69.2%) and cefaclor, which showed the greatest difference between breakpoints: 0% by EUCAST, 28.2% by PK/PD and 73.1% by CLSI. All S. pneumoniae isolates were susceptible to amoxicillin/clavulanic acid by CLSI and PK/PD breakpoints. H. influenzae isolates were almost all β-lactamase negative (90.9%). One isolate was β-lactamase negative and ampicillin resistant (BLNAR) by CLSI and four isolates were BLNAR by EUCAST criteria. Susceptibility of isolates was high (≥90.9%) by CLSI breakpoints for all antibiotics tested except trimethoprim/sulfamethoxazole (61.6%). Susceptibility using EUCAST breakpoints was similar for ampicillin (90.9%) and amoxicillin/clavulanic acid (95%) but was low for cefuroxime (oral), where only 10.1% of isolates were susceptible. All S. pneumoniae and H. influenzae isolates were susceptible to the fluoroquinolones by all breakpoints. Susceptibility to ceftriaxone was also 100% for H. influenzae and ≥91% for S. pneumoniae isolates by all breakpoints. The application of different EUCAST breakpoints for low and higher doses for some of the antibiotics (amoxicillin, amoxicillin/clavulanic acid, ampicillin, penicillin, ceftriaxone, clarithromycin, erythromycin, levofloxacin and trimethoprim/sulfamethoxazole) allowed, for the first time in a SOAR study, the effect of raising the dosage on susceptibility to be quantified. CONCLUSIONS: Antibiotic susceptibility in these respiratory tract pathogens was generally high in Ukraine. These data are important for empirical therapy choices in the treatment of CA-RTIs.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Torumkuney D, Bratus E, Yuvko O, et al. Results from the Survey of Antibiotic Resistance (SOAR) 2016-17 in Ukraine: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. J Antimicrob Chemother. 2020. PMID: 32337596. doi:10.1093/jac/dkaa087

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。